MacuLogix® Appoints Dr. Amanda K. Lee as Director of Professional Relations

Monday, July 9, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

MIDDLETOWN, Pa., July 9, 2018 /PRNewswire/ -- MacuLogix Inc., the only company to equip eye care professionals with the instrument,

tools and education needed to effectively diagnose and treat patients with age-related macular degeneration (AMD), announces that Amanda K. Lee, OD, has joined MacuLogix as director of professional relations, effective immediately. In this critical role,
Dr. Lee will serve as a clinical partner to MacuLogix customers, eye care professionals and industry partners. Dr. Lee will focus on advancing the standard of care for age-related macular degeneration to improve patient outcomes. 

"We couldn't be more thrilled to have Dr. Lee join our team. She is not only an experienced and influential optometrist, she is also an early adopter of the AdaptDx," said William McPhee, president and CEO of MacuLogix. "She is uniquely qualified to advise our customers since she has built an extremely successful AMD clinic from the ground up."

Prior to joining MacuLogix, Dr. Lee served as vice president/COO/co-owner of Vision Source at Seaside Eye Associates in Myrtle Beach, South Carolina. She serves as an administrator in South Carolina for Vision Source. She is a current member of the South Carolina Optometric Physicians Association and has been a member of the American Optometric Association for the past 25 years.

"I can't imagine joining a team of people more aligned with every eye care provider's goal of helping people by preserving their vision. While I feel we take great care of our patients in our local clinic, there is a limited number of people we can see each year. However, if I can teach other doctors how to incorporate AdaptDx technology into their clinics so that they can save their patients' sight, then the impact becomes exponential!" said Dr. Lee. "In my opinion, no one should lose their sight to AMD — not with today's technology. MacuLogix is the perfect place for me to take the next step in my optometric career and I couldn't be more excited to start this new chapter."

In addition to practicing optometry for 20 years, Dr. Lee has been a professional speaker and consultant for Alcon, Bausch & Lomb and MacuLogix. She earned her BA in Biology from Central Connecticut State University before earning a BS in Visual Science and Doctorate of Optometry from Pennsylvania College of Optometry. She also completed a Residency in Primary Care/Ocular Disease at The Eye Institute in Philadelphia, Pennsylvania. She will continue to live with her family in Myrtle Beach, South Carolina, when she's not on the road with MacuLogix.

About MacuLogix®

MacuLogix Incequips eye care professionals with the instrument, tools and education needed to effectively diagnose and treat patients with AMD. By leveraging the science of dark adaptation through its AdaptDx®, MacuLogix is working to eliminate preventable blindness caused by AMD, a chronic, progressive disease that impacts over 170 million people worldwide and goes undiagnosed in 25 percent of patients. Through its AdaptDx® dark adaptation biomarker, MacuLogix enables eye care professionals to detect, monitor and treat AMD three years before it can be seen clinically. MacuLogix provides in-practice training and treatment best practices to support the implementation and optimization of the AdaptDx®. Visit for additional information. 

Media Contact:

Amy 304-6746

Cision View original content:

SOURCE MacuLogix

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store